{"id":"W4395025680","doi":"10.1093/rheumatology/keae235","title":"Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial","year":2024,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Western University","funders":"Seagen; Mallinckrodt Pharmaceuticals; Scleroderma Society of Ontario; AbbVie; AstraZeneca","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Adverse effect; Placebo; Clinical endpoint; Refractory (planetary science); Surgery; Gastroenterology; Oncology; Clinical trial; CD30; Pathology; Lymphoma","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001710359,0.000942871,0.001272737,0.0001894838,0.0002563613,0.0007743277,0.0005383939,0.0009753769,0.002969448],"category_scores_gemma":[0.0008878477,0.0002590893,0.0008041824,0.0002062311,0.0005439488,0.0005580934,0.0001947208,0.001772216,0.0004360001],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000441962,"about_ca_system_score_gemma":0.000758081,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003401528,"about_ca_topic_score_gemma":0.001045756,"domain_scores_codex":[0.999602,0.0002209434,0.00002543925,0.00005283934,0.00004354494,0.00005529873],"domain_scores_gemma":[0.999337,0.0002110765,0.0001567269,0.00003778137,0.00005334683,0.0002039396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8280938,0.02444944,0.004117158,0.003015492,0.001636371,0.0003079624,0.0002651667,0.001640371,0.02876709,0.0002529258,0.002019207,0.1054351],"study_design_scores_gemma":[0.8053002,0.186175,0.00458109,0.00008338445,0.0002531167,0.0001882906,0.00003516905,0.0007286685,0.001318096,0.0001012784,0.001224332,0.00001131855],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902535,0.005827668,0.0004693084,0.0003100555,0.0001203826,0.001433287,0.0004066104,0.00005131721,0.001127862],"genre_scores_gemma":[0.9940598,0.002141195,0.0007505571,0.000396159,0.000188491,0.001024025,0.00049729,0.000007787079,0.0009346901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002969448,"threshold_uncertainty_score":0.00993377,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0685092467611269,"score_gpt":0.3181994637411705,"score_spread":0.2496902169800436,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}